c-erbB-2 and p53 expression in breast cancer fine needle aspirates

Cytopathology

Volumn 7, Issue 3, 1996, Pages 178-186

  Tiniakos, D G ^a,c   Robinson, K B ^b   Greenwood, H ^b   Cullen, P ^b   Cook, A I M ^b   Horne, C H W ^a   Angus, B ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH DURHAM   (United Kingdom)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

breast cancer; c erbB 2; fine needle aspirate; immunocytochemistry; p53

Indexed keywords

PROTEIN P53; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CANCER GRADING; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LYMPH NODE METASTASIS; MENOPAUSE; ONCOGENE C ERB; PRIORITY JOURNAL; TUMOR VOLUME; ADULT; AGED; BIOSYNTHESIS; BREAST TUMOR; CARCINOMA; CHEMISTRY; COMPARATIVE STUDY; FEMALE; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029665315     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2303.1996.39482394.x     Document Type: Article

References (34)

1. Akiyama T, Sudo C, Ogawarwa H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-6.
2. Yamamoto T, Ikawa S, Akiyama T et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 1986; 319: 230-4.
3. Dawkins HJS, Robbins PD, Smith KL et al. Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease. Path Res Pract 1993; 189: 1233-52.
4. Dawkins HJS, Robbins PD, Sarna M, Carrello S, Harvey JM, Sterrett GF. c-erbB-2 amplification and overexpression in breast cancer: evaluation and comparison of Southern blot, slot blot, ELISA and immunohistochemistry. Pathology 1993; 25: 124-9.
5. Slamon DJ, Gogolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
6. Gullick WJ, Love SB, Wright C et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63: 434-8.
7. Wright C, Nicholson S, Angus B et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118-21.
8. Baker SJ, Fearon ER, Nigro JM et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244: 217-21.
9. Levine AJ, Momand J, Finlay CA. The p53 tumour-suppressor gene. Nature 1991; 351: 453-6.
10. Lane DP, Benchimal S. p53: oncogene or anti-oncogene? Gene Dev 1990; 4: 1-8.
11. Kern SE, Pietenpol JA, Thaingalingam S et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256: 827-30.
12. Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-16.
13. Iwaya K, Tsuda H, Hiraide H et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991; 82: 835-40.
14. Sawan A, Randall B, Angus B et al. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol 1992; 168: 23-28.
15. Yamashita H, Kobayashi S, Iwase H et al. Analysis of oncogenes and tumour suppressor genes in human breast cancer. Jpn J Cancer Res 1993; 84: 871-8.
16. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S. Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. Am J Clin Pathol 1993; 100: 213-7.
17. Spandidos DA, Karaiossifidi H, Malliri A et al. Expression of ras. Rb1 and p53 proteins in human breast cancer. Anticancer Res 1992; 12: 81-90.
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
19. Shi SR, Key ME, Karla KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39: 741-8.
20. Vetrani A, Fulciniti F, Di Benedetto G et al. Fine-needle aspiration biopsies of breast masses. An additional experience with 1153 cases (1985 1988) and a meta-analysis. Cancer 1992; 69: 736-40.
21. Cook AIM, Robinson KB. Aspiration cytology of the breast with immediate reporting: initial experience with 1000 patients in a district general hospital. J R Coll Surg Edinb 1991; 36: 289-92.
22. Scopa CD, Koukouras D, Spiliotis J et al. Comparison of fine needle aspiration (FNA) and Trucut biopsy of palpable mammary lesions. Cancer Detect Prev 1996; 19: in press.
23. Fernando IN, Allan SM, Sandle J, Dean C, Sacks N, Trott PA. Immunocytochemical staining for the c-erbB-2 gene product in breast aspirates: a preliminary report. Cytopathology 1993; 4: 219-24.
24. Troncone G, Zeppa P, Fulciniti F et al. c-erbB-2 expression and DNA ploidy status in breast cancer cells obtained by fine needle aspiration (FNA). Cytopathology 1993; 4: 195-205.
25. Stephenson TJ, Royds JA, Silcocks PB, Brammer HJ, Shorthouse AJ, Underwood JCE. Diagnostic associations of p53 immunostaining in the fine needle aspiration cytology of the breast. Cytopathology 1994; 5: 146-53.
26. Tiniakos DG, Healicon RM, Hair T, Horne CHW, Wadehra V, Angus B. p53 immunostaining as a marker of malignancy in cytological preparations of body fluids. Acta Cytologica 1995; 39: 171-6.
27. Koutselini H, Malliri A, Field JK, Spandidos DA. p53 expression in cytologic specimens from benign and malignant breast lesions. Anticancer Res 1991; 11: 1415-9.
28. Soini Y, Mannermaa A, Winqvist R et al. Application of FNA to the demonstration of c-erbB-2 and c-myc expression by in situ hybridisation in breast carcinoma. J Histochem Cytochem 1994; 42: 795-803.
29. Lonn U, Lonn S, Nilsson B, Stenkvist B. Intratumoral heterogeneity for amplified genes in human breast carcinoma. Int J Oncol 1994; 58: 40-45.
30. Bacus SS, Ruby SG, Weinberg DS et al. HER-2/ neu oncogene expression and proliferation in breast cancer. Am J Pathol 1990; 137: 103-11.
31. Poller DN, Silverstein M, Galea M et al. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification. Association between cellular proliferation and c-erbB-2 protein expression. Modern Pathology 1994; 7: 257-62.
32. Allan SM, Fernando IN, Sandle J, Trott PA. Expression of the c-erbB-2 gene product as detected in cytologic aspirates in breast cancer. Acta Cytologica 1993; 37: 981-2.
33. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO. p53 protein expression in mammary ductal carcinoma in situ. Hum Pathol 1993; 24: 463-8.
34. Marks JR, Humphrey PA, Wu K et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994; 219: 332-41.